Acknowledging the immunal deficiency, we recommended that all the patients with Furhman grades 2–3 or 3 accepted cytokine therapy, but only 2 patients with Furman grades 2–3 (histological type: clear cell carcinoma, partially clear cell, and partially papillary carcinoma) accepted cytokine therapy including IL-2 and IFN. This evidence concerns the gene IFNA1 and clear cell adenocarcinoma.